ArticleMetabolic brain disease2026
Decanoic acid modulates cerebral metabolism and attenuates ischemic injury in a mouse model.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral ischemia, resulting from acute interruption of cerebral blood flow, is a leading cause of long-term cognitive and motor disabilities, and current therapeutic options remain limited. Decanoic acid, a medium-chain fatty acid with antioxidant and anti-inflammatory properties, has been proposed as a potential neuroprotective agent. This study evaluated the neuroprotective and metabolic effects of decanoic acid in a murine model of permanent middle cerebral artery occlusion (MCAO). Male mice received decanoic acid (62.5, 125, or 250 mg/kg, oral gavage) or vehicle for 7 days after MCAO. Infarct volume was quantified by TTC staining. Motor and cognitive performance were assessed using the Cylinder, Limb Clasping, Object Location, and Novel Object Recognition tests. Metabolomic profiling (HS/GC–MS) of cortical tissue was performed to characterize ischemia-induced metabolic disturbances and treatment-related modulation of lipid and energy metabolism. Oxidative stress markers, antioxidant enzyme activities, and inflammatory cytokines (ELISA) were also measured in brain tissue. Decanoic acid significantly reduced total infarct volume and improved motor coordination and memory performance. Metabolomic analysis revealed that DA modulated metabolites disrupted by ischemia, partially restoring lipid and aldehyde homeostasis. Furthermore, treatment decreased lipid peroxidation, enhanced antioxidant enzyme activities, and effectively reversed the ischemia-induced elevation of pro-inflammatory cytokines, thereby neutralizing the neuroinflammatory response. These findings suggest that decanoic acid may exert a coordinated regulatory effect, contributing to neuroprotection through the modulation of cerebral metabolic homeostasis and attenuation of oxidative and inflammatory stress, and supporting its potential as a therapeutic candidate for ischemic brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.